The drug screen study was designed to assess the anti-cancer activity of the selected compounds using a standard cell proliferation assay procedure, against nine human cancer cell lines.
The data showed the anti-proliferative and cytotoxic effects against a range of tumour cell lines following treatment with three of the company’s proprietary compounds.
The data also showed a positive outcome of a in-vivo study which was designed to test the effectiveness of two test compounds against tumours.
Heartlink CEO Tracey-Anne Dickens said data collected provides a basis on which to further develop the proprietary compounds and to seek alliances for research and development or commercialisation.